In a report issued on May 3, Sean Lavin from BTIG maintained a Hold rating on Abiomed (NASDAQ: ABMD). The company’s shares closed on Friday at $349.28, close to its 52-week high of $352.15.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 15.0% and a 63.2% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Boston Scientific Corp, and Varian Medical Systems.
Abiomed has an analyst consensus of Strong Buy, with a price target consensus of $320.
See today’s analyst top recommended stocks >>
Based on Abiomed’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $174 million and quarterly net profit of $36.85 million. In comparison, last year the company earned revenue of $125 million and had a net profit of $14.9 million.
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded in 1981 and is headquartered in Danvers, MA.
